Magnet Update
Covid 19 Update
About ResMed
Healthcare Professionals

FACE study

face-study-ResMed

The FACE study is a French and Belgium prospective, multicentre, observational cohort that will provide long-term data on morbidity and mortality of heart failure (both HFrEF and HFpEF) patients using ASV. So far over 400 patients have been enrolled by 30 centres. Since May 2015, the recruitment has been limited to patients with HFpEF, with a target of 300 chronic HFpEF patients.

Interim data results

FACE-study-interim-data-resmed

Interim data from the FACE cohort seems to confirm these findings1, and provide some positive insights in HFpEF:

  • The FACE prospective cohort aimed to provide real-world data about the prognosis of HF patients with CSA treated with ASV. This interim analysis provides some long-term morbidity and mortality data of 391 HF patients (HFrEF, HFmrEF or HFpEF) eligible to ASV therapy followed during 2 years.
  • Severe hypoxemia (high T90) during sleep is a strong independent risk factor for mortality in HF patients (HR=12).
  • ASV therapy was associated with a better prognosis in CHF patients with severe nocturnal hypoxaemia or non-ischemic etiology, especially in subgroups with middle-range or preserved LVEF but not with reduced LVEF.

Support for investigator initiated research

ResMed believes in the need to support ethical, independent clinical research, conducted by qualified third-party investigators.

Read more

References

1

R Tamisier et al: Late Breaking Abstract – Morbidity and mortality of chronic heart failure (CHF) patients with central sleep apnea (CSA) treated by adaptive servoventilation (ASV): Interim results of FACE cohort study_Update. ERJ September 2017 Supplement.

1

R Tamisier et al: Late Breaking Abstract – Morbidity and mortality of chronic heart failure (CHF) patients with central sleep apnea (CSA) treated by adaptive servoventilation (ASV): Interim results of FACE cohort study_Update. ERJ September 2017 Supplement.

© 2020 ResMed All rights reserved